Audiomedica.com
PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 10:30:00
- Mas informaciones
Informações:
Sinopsis
The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab extended overall survival when compared head-to-head with docetaxel among patients with previously-treated non-small cell …161205-ajo-fabrice-barlesi-esmo-production-master-6-3m-10-30secs
